tiprankstipranks
Trending News
More News >
SAB Biotherapeutics (SABS)
NASDAQ:SABS
US Market
Advertisement

SAB Biotherapeutics (SABS) Ratios

Compare
154 Followers

SAB Biotherapeutics Ratios

SABS's free cash flow for Q2 2025 was $0.00. For the 2025 fiscal year, SABS's free cash flow was decreased by $ and operating cash flow was $0.00. See a summary of the company’s cash flow.
Ratios
TTM
Dec 24Dec 23Dec 22Dec 21
Liquidity Ratios
Current Ratio
0.87 5.45 1.47 1.96 3.11
Quick Ratio
0.87 5.45 1.47 1.96 3.11
Cash Ratio
0.35 5.23 1.00 1.35 1.14
Solvency Ratio
-1.86 -1.44 -0.78 -0.39 1.18
Operating Cash Flow Ratio
-3.57 -2.32 0.25 0.15 0.90
Short-Term Operating Cash Flow Coverage
-39.56 -23.90 2.69 2.09 18.57
Net Current Asset Value
$ -8.81M$ 32.27M$ 2.25M$ 7.60M$ 16.92M
Leverage Ratios
Debt-to-Assets Ratio
0.21 0.07 0.12 0.08 0.14
Debt-to-Equity Ratio
0.53 0.10 0.19 0.17 0.21
Debt-to-Capital Ratio
0.35 0.09 0.16 0.15 0.17
Long-Term Debt-to-Capital Ratio
0.31 0.00 0.02 0.00 <0.01
Financial Leverage Ratio
2.51 1.46 1.64 2.06 1.45
Debt Service Coverage Ratio
-27.23 -27.91 -8.92 -7.41 20.50
Interest Coverage Ratio
-147.87 -120.77 -95.89 -45.48 43.82
Debt to Market Cap
0.29 0.03 0.08 <0.01 <0.01
Interest Debt Per Share
0.72 1.13 1.43 2.57 3.39
Net Debt to EBITDA
-0.08 1.33 0.60 1.74 -0.21
Profitability Margins
Gross Profit Margin
797878.29%-67.28%86.23%97.28%100.00%
EBIT Margin
8968762.20%-1870.42%-77.03%-27.68%37.27%
EBITDA Margin
8274161.22%-1703.14%-63.26%-24.96%38.26%
Operating Profit Margin
10200502.68%-1700.56%-120.97%-22.00%37.22%
Pretax Profit Margin
9037870.73%-1884.50%-78.29%-28.16%36.42%
Net Profit Margin
9037870.73%-1884.50%-78.40%-28.66%36.42%
Continuous Operations Profit Margin
9037870.73%-1884.50%-78.40%-28.16%36.42%
Net Income Per EBT
100.00%100.00%100.14%101.75%100.00%
EBT Per EBIT
88.60%110.82%64.72%128.01%97.86%
Return on Assets (ROA)
-122.99%-50.27%-36.82%-21.98%35.58%
Return on Equity (ROE)
-153.92%-73.64%-60.34%-45.25%51.57%
Return on Capital Employed (ROCE)
-215.00%-52.07%-80.52%-24.49%45.20%
Return on Invested Capital (ROIC)
-204.86%-50.78%-76.34%-23.58%42.59%
Return on Tangible Assets
-122.99%-50.27%-36.82%-21.98%35.58%
Earnings Yield
-185.43%-111.07%-72.99%-8.17%7.81%
Efficiency Ratios
Receivables Turnover
0.00 0.00 4.30 7.60 2.69
Payables Turnover
0.35 3.96 0.89 0.37 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
>-0.01 0.09 0.84 1.97 2.50
Asset Turnover
>-0.01 0.03 0.47 0.77 0.98
Working Capital Turnover Ratio
>-0.01 0.08 1.55 2.58 3.94
Cash Conversion Cycle
-1.04K -92.19 -323.09 -936.10 135.92
Days of Sales Outstanding
0.00 0.00 84.85 48.03 135.92
Days of Inventory Outstanding
0.00 0.00 0.00 0.00 0.00
Days of Payables Outstanding
1.04K 92.19 407.94 984.13 0.00
Operating Cycle
0.00 0.00 84.85 48.03 135.92
Cash Flow Ratios
Operating Cash Flow Per Share
-4.10 -4.55 0.86 1.37 3.94
Free Cash Flow Per Share
-4.12 -4.59 -1.65 -2.63 -1.07
CapEx Per Share
0.02 0.04 2.51 4.00 5.01
Free Cash Flow to Operating Cash Flow
1.00 1.01 -1.91 -1.91 -0.27
Dividend Paid and CapEx Coverage Ratio
-244.77 -127.41 0.34 0.34 0.79
Capital Expenditure Coverage Ratio
-244.77 -127.41 0.34 0.34 0.79
Operating Cash Flow Coverage Ratio
-5.94 -4.25 0.63 0.56 1.23
Operating Cash Flow to Sales Ratio
92.94K -11.22 0.16 0.06 0.18
Free Cash Flow Yield
-170.93%-66.64%-27.98%-3.37%-1.06%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
-0.54 -0.90 -1.37 -12.24 12.81
Price-to-Sales (P/S) Ratio
-54.59K 16.97 1.07 3.51 4.67
Price-to-Book (P/B) Ratio
1.66 0.66 0.83 5.54 6.61
Price-to-Free Cash Flow (P/FCF) Ratio
-0.59 -1.50 -3.57 -29.72 -94.51
Price-to-Operating Cash Flow Ratio
-0.52 -1.51 6.83 56.81 25.76
Price-to-Earnings Growth (PEG) Ratio
0.07 -0.01 0.04 0.07 >-0.01
Price-to-Fair Value
1.66 0.66 0.83 5.54 6.61
Enterprise Value Multiple
-0.74 0.33 -1.09 -12.31 11.98
Enterprise Value
25.11M -12.67M 16.56M 187.06M 253.24M
EV to EBITDA
-0.74 0.33 -1.09 -12.31 11.98
EV to Sales
-61.24K -5.66 0.69 3.07 4.58
EV to Free Cash Flow
-0.66 0.50 -2.30 -26.03 -92.87
EV to Operating Cash Flow
-0.66 0.50 4.41 49.77 25.31
Tangible Book Value Per Share
1.29 10.38 7.14 14.10 15.36
Shareholders’ Equity Per Share
1.29 10.38 7.14 14.10 15.36
Tax and Other Ratios
Effective Tax Rate
0.00 0.00 >-0.01 -0.02 0.02
Revenue Per Share
>-0.01 0.41 5.49 22.27 21.75
Net Income Per Share
-3.99 -7.64 -4.31 -6.38 7.92
Tax Burden
1.00 1.00 1.00 1.02 1.00
Interest Burden
1.01 1.01 1.02 1.02 0.98
Research & Development to Revenue
-73.45K 7.38 1.52 0.94 0.51
SG&A to Revenue
-29.27K 10.63 0.69 0.28 0.12
Stock-Based Compensation to Revenue
-8.72K 1.08 0.11 0.04 0.02
Income Quality
0.95 0.60 -0.22 -0.22 0.50
Currency in USD
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis